PROBLEM TO BE SOLVED: To provide a stable transdermal drug delivery device which can improve the rate of absorption from the skin for various therapeutic agents.SOLUTION: The invention provides a transdermal drug delivery device consisting of an adhesive layer which is a solid dispersion material consisting of a combination polymeric stabilizing and dispersing agent comprising adhesives, a therapeutic agent in amorphous form, and a hydrogen bond-forming functional group； and a manufacturing method of the device concerned. The combination polymeric stabilizing and dispersing agent are polyvinylpyrrolidone, and (i) the therapeutic agent in the amorphous form concerned has a glass transition temperature of at least 70°C, and the weight ratio of the therapeutic agent in the amorphous form concerned to the combination polymeric stabilizing and dispersing agent concerned is 0.5-5； or (ii) the therapeutic agent in the amorphous form concerned has a glass transition temperature of less than 40°C, and the weight ratio of the therapeutic agent concerned to the combination polymeric stabilizing and dispersing agent concerned is 2-10. The transdermal drug delivery device is further characterized by the long-term stability of the therapeutic agent dependent upon the ratio of the therapeutic agent to the polymeric stabilizing and dispersing agent.【課題】様々な治療薬のための皮膚からの吸収速度を改良できる安定な経皮薬物送達デバイスの提供。【解決手段】接着剤、アモルファス形の治療薬、及び水素結合形成官能基を含む兼用ポリマー性安定及び分散剤からなる固体分散物である接着剤層からなる経皮薬物送達デバイスであって、当該兼用ポリマー安定及び分散剤がポリビニルピロリドンであり、（ｉ）当該アモルファス形の治療薬が少なくとも７０℃のガラス転移温度を有し、当該ポリマー性安定及び分散剤対当該アモルファス形の治療薬の重量比が０．５～５である；又は、（ｉｉ）当該アモルファス形の治療薬が４０℃未満のガラス転移温度を有し、当該ポリマー性安定及び分散剤対当該治療薬の重量比が２～１０である経皮薬物送達デバイス、及び当該デバイスの製造法。該経皮薬物送達デバイスは、更に治療薬対ポリマー性安定及び分散剤の比率に依存した、治療薬の長期安定性も特徴とする。【選択図】図１
